Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study

Diabetes, obesity & metabolism · 2026 Nov 9 · Labate AM, Villari P et

By Maren Holt · Senior Reporter, GLP-1

Nov 8 19:00 ETSource: Diabetes, obesity & metabolism

From the source

Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study
Diabetes, obesity & metabolism · 2026 Nov 9 · Labate AM, Villari P et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/43003421/